Deutsche Bank downgraded Akorn, Inc. (NASDAQ: AKRX) to Hold from Buy as the stock has recovered since the post-third quarter correction. According to Deutsche Bank, further upside will depend on “hard-to-call dynamics of new product approvals...
WASHINGTON (dpa-AFX) - Akorn Inc (AKRX) announced a profit for fourth
quarter that dropped from last year.
The company said its bottom line declined to $72.32 million, or $0.58 per share.
This was lower than $76.01 million, or $0.60 per share,...
WASHINGTON (dpa-AFX) - Akorn Inc. (AKRX) has received FDA approval for
Mycophenolate Mofetil for Injection, USP, 500 mg/vial, a generic version of
Mycophenolate Mofetil is indicated for preventing organ rejection...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Akorn (AKRX):